Natixis Advisors LLC Acquires 7,670 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Natixis Advisors LLC boosted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 40.4% in the third quarter, HoldingsChannel reports. The firm owned 26,675 shares of the company’s stock after purchasing an additional 7,670 shares during the period. Natixis Advisors LLC’s holdings in Structure Therapeutics were worth $1,171,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $39,000. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the period. Quarry LP acquired a new position in shares of Structure Therapeutics during the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after acquiring an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics in the third quarter worth $202,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Price Performance

GPCR opened at $33.74 on Wednesday. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38. The firm has a market capitalization of $1.93 billion, a P/E ratio of -45.59 and a beta of -3.23. The company’s 50-day moving average is $38.58 and its 200 day moving average is $39.50.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. JMP Securities cut their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.